What Long-Term Investors Should Know About This Hims Insider Filing
Key Points
This disposition of 47,702 shares was executed at $28.15 per share for a total transaction value of $1.3 million.
This activity was non-discretionary, as shares were withheld to satisfy tax liabilities associated with the quarterly vesting of restricted stock units.
The executive's direct Class A stock ownership remains at 470,687 shares, representing a market value of $13.3 million as of the transaction date.
- 10 stocks we like better than Hims & Hers Health ›
Chief Operating Officer Michael Chi disposed of 47,702 shares of Hims & Hers Health, Inc. (NYSE:HIMS) on August 14, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.3 million |
| Shares sold | 47,702 |
| Post-transaction shares (directly held) | 470,687 |
| Post-transaction value | $13.3 million |
Transaction value based on SEC Form 4 weighted average sale price ($28.15); post-transaction value based on the August 14 market close ($28.15).
Key questions
- What was the structural driver of this transaction?
The disposition was non-discretionary and served to cover tax obligations linked to the vesting of multiple restricted stock unit awards. This type of automated withholding reflects a pre-arranged tax settlement rather than an active investment decision by the Chief Operating Officer. - What is the status of the insider's remaining equity exposure?
Following the settlement, Chi directly holds 470,687 shares of Class A Common Stock. The executive also maintains derivative securities in the form of unvested restricted stock units, which will continue to vest quarterly through mid-2029. - How has the stock performed relative to this vesting event?
The one-year total return for the stock was -40% as of the August 14 transaction date. Shares were priced at $28.15 for this withholding event, while the stock was priced at $28.61 as of the August 17 market close. - What is the forward outlook for additional vesting events?
Disclosure footnotes specify quarterly vesting dates for five separate restricted stock unit grants with schedules extending through June 2029. These overlapping awards ensure a consistent cadence of equity delivery and associated tax-related dispositions over the coming 12 quarters.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-17) | $28.61 |
| Market Capitalization | $6.4 billion |
| Revenue (TTM) | $2.6 billion |
| Net Income (TTM) | -$142.0 million |
Company Snapshot
- Hims & Hers operates a comprehensive digital health platform that delivers prescription medications, over-the-counter drugs, medical devices, cosmetics, and dietary supplements directly to consumers through its websites and mobile application.
- The company generates revenue through a direct-to-consumer model by connecting patients with licensed medical professionals for virtual consultations and facilitating the sale of health and wellness products with recurring subscription and transaction-based revenue streams.
- The company primarily serves consumers seeking convenient, accessible healthcare solutions and wellness products, targeting individuals who prefer digital-first medical consultations and home delivery of pharmaceutical and consumer health products.
Hims & Hers Health operates as a leading digital health platform with a $6.4 billion market capitalization and $2.6 billion in TTM revenue, positioning itself at the intersection of telehealth and direct-to-consumer pharmaceutical distribution. The company's integrated platform model creates competitive advantages through operational efficiency, customer convenience, and data-driven personalization. Despite current net losses of $142.0 million TTM, the company's substantial revenue base and market scale reflect strong consumer adoption of its digital-first healthcare delivery model.
What this transaction means for investors
A key thing that sticks out about this filing is that Chi carries five separate RSU grants that vest quarterly out through June 2029. That shows you that this kind of automatic withholding sale isn't a one-off, and it also shows you he has plenty of reason to ensure HIMS stock keeps going up, even if the past year has been tough on the market. Those RSUs total up to nearly 600,000, so they're clearly substantial.
As COO, Chi is the one running the operational side of a company that just took on a lot at once. Hims & Hers closed its Eucalyptus acquisition in June, the largest in company history, and international revenue jumped to $131.4 million in the second quarter from $7.5 million a year earlier. CFO Yemi Okupe told investors the international business is expected to generate at least $600 million in 2026 revenue while operating "at or near breakeven" on adjusted EBITDA. Ultimately, that's the trade-off Chi is actually managing, fast global scale against thin near-term profitability, and it's a better gauge of his read on the business than a scheduled tax sale.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,970!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,040!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 19, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy.
Recommended Articles
